Jeremy Bender, Ph.D., M.B.A. has served as our Chief Executive Officer, President and a member of our board of directors since September 2020. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences, a pharmaceutical company, from March 2018 to September 2020.

Prior to that, he was Chief Operating Officer of Tizona Therapeutics from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma, a biotechnology company specializing in cancer and autoimmune therapeutics, from October 2012 to July 2015. Prior to joining Sutro Biopharma, he was Vice President of Corporate Development at Allos Therapeutics, a biotechnology company focused on cancer treatments, from January 2006 to September 2012.

Dr. Bender also sits on the board of Mereo BioPharma as an independent board member. He started his career in the life sciences practice at Boston Consulting Group, a management consulting company.

Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management.

Dr. Barry is a board-certified pediatrician and pediatric hematologist/oncologist with over 15 years of experience in drug development. Prior to joining Day One in 2021, she was Global Clinical Lead for Pediatric Oncology at Pfizer, as well as Head of Pfizer’s Pediatric Oncology Leadership Team where she oversaw more than 10 pediatric oncology clinical programs.

She has also held previous roles at Genzyme and Millenium/Takeda focused on the development of oncology therapeutics in adults. Dr. Barry serves on the Industry Advisory Council for CureSearch and is a member of the ACCELERATE Platform Steering Committee. She is also a co-chair of the Children’s Oncology Group Industry Relations Council.

Dr. Barry is a graduate of the pediatric hematology/oncology fellowship program at the Dana Farber Cancer Institute and Children’s Hospital Boston, and the pediatric residency program at Tufts. She received her M.D. at Yale University School of Medicine and also obtained a Masters in Medical Science degree from Harvard Medical School.

Dr. Davy Chiodin brings to Day One more than 20 years of pharmaceutical industry experience when he mostly focused on oncology drug development, across tumor types, stages of development, and geographies. In his role, Davy oversees Program Leadership, Regulatory Science and Quality Assurance, Development Operations, and Biometrics.

Prior to joining Day One, Davy was at Acerta, a member of the AstraZeneca group, where he was Vice President, Regulatory Science and Quality Assurance through the acalabrutinib global filings and the build of the AZ hematology franchise. Prior to that, Davy spent more than 10 years at Roche/Genentech, assuming roles of increased responsibility in the Regulatory function in both Europe and the US, including 2 years fully dedicated to the pediatric oncology portfolio.

He has remained an active contributor to the pediatric oncology community since then. Davy received his PharmD from the University of Grenoble, France, and a Master in Regulatory Affairs and Pharmacoeconomics from the universities of Lille and Paris, France.

Adam Dubow joined Day One as General Counsel in October 2022 following a 22-year tenure at Bristol Myers Squibb, where he most recently served as Chief Compliance and Ethics Officer, establishing a best-in-class global compliance program.

In addition to serving on the Bristol Myers Squibb’s management team, Adam previously served as the Company’s Lead Counsel for the Global Research and Development organization. Prior to this role, he directed the Legal Teams for the Europe, Middle East & Africa, as well as the Asia Pacific and Japan Regions. He also created and led the Global Corporate Policy function at Bristol Myers Squibb.

Prior to joining Bristol Myers Squibb, Adam was a Partner at Sedgwick, Detert, Moran & Arnold, where he specialized in products liability litigation. Adam currently serves on the Global Board of the Healthcare Businesswomen’s Association. He holds an undergraduate degree from Brandeis University, and a J.D. from Fordham University School of Law. Adam is a member of the New York State Bar.

Lauren Merendino is a seasoned commercial leader with over 25 years of pharmaceutical & biotech leadership with expertise in building and leading commercial teams and a record of successful product launches. In her current role, she has led the launch of our inaugural product, OJEMDA, delivering outstanding performance.

Previously, as Chief Commercial Officer at Myovant Sciences, Lauren led the successful launches of two products across 3 indications in the span of 2 years. Lauren spent the majority of her career at Genentech/Roche, where she held various commercial leadership roles on multiple launches. In her final role at Genentech, she was the Head of the Neurological Rare Diseases therapeutic area where she led a cross-functional team to launch a novel therapy in SMA, which quickly grew to become the market leader.

Lauren’s career is built on a deep foundation of Marketing, Sales and leadership experience, with a depth of experience from over 15 years in oncology. Lauren also served as a Director on the Board of ESSA Pharmaceuticals from June 2023 to March 2025. Lauren has a Bachelors of Science in Microbiology from Penn State University and completed her MBA at New York University.

Jaa Roberson has 23 years of human resources experience across the biopharma, health insurance, and retail industries. Most recently, she was the head of human resources for Bellicum Pharmaceuticals, a clinical-stage biopharmaceutical company focused on cellular Immuno-Oncology.

Previously, she served as the head of human resources for Achaogen. Before that, she spent six years at Genentech/Roche supporting the BioOncology Business Unit, the Neuroscience and Rare Diseases Business Unit, and the Immunology & Ophthalmology Business units.

Earlier in her career, Ms. Roberson held human resources roles at Blue Shield of CA, Levi Strauss, and Williams-Sonoma. Ms. Roberson earned her Bachelor of Arts from Rice University and her Master of Music in Violin Performance from the San Francisco Conservatory of Music.

John brings more than 25 years of experience and leadership in commercial operations to Day One. Most recently, he was Chief Operating Officer at Nutcracker Therapeutics where he led CMC, IT, and financial operations.

Prior to Nutcracker, John was Vice President of Commercial Operations at Gilead Sciences following the acquisition of Immunomedics, leading the development and commercialization of the company’s Biologics and Antibody Drug Conjugate (ADC) portfolio.

His experience includes business strategy across various product modalities, including vaccines and synthetic peptides/molecules. John received a PhD in Chemical Engineering from The University of Pennsylvania and an MBA from The Wharton School of Business.

Dr. Vasconcelles is a life science leader with over 25 years of experience as an academic physician and hematologist/oncologist with research and development (R&D) and executive leadership roles across the biopharmaceutical and health technology industries.

Most recently, he served as Executive Vice President and Head of Research, Development, and Medical Affairs at ImmunoGen, where he helped transform the company into a global biotech enterprise.

Prior to that, Dr. Vasconcelles was Chief Medical Officer and Head of the Medical and Scientific Organization at Flatiron Health, a subsidiary of the Roche Group; Chief Medical Officer at Unum Therapeutics; Head of Oncology R&D at Takeda Pharmaceuticals; and Global Therapeutic Area Head, Oncology and Transplantation at Genzyme (now Sanofi). In addition, he served as a faculty member of the Harvard Medical School and was an associate physician at the Beth Israel Hospital, the Brigham and Women’s Hospital and the Dana-Farber Cancer Institute during the period from 1996 to 2021.

Dr. Vasconcelles currently serves as an Independent Director of Molecular Partners AG and Kura Oncology Inc. and is an advisor for several biotech companies. He earned his B.A. and M.D. from Northwestern University.

Mr. Charles York II joined Day One in 2021. He has over 20 years of experience in corporate finance in public and private enterprises in transactional and strategic capital formation roles, notably, operations, corporate and business development in the biotechnology industry.

Previously, Mr. York served as Chief Financial Officer and Head of Corporate Development of Aeglea Biotherapeutics, a biotechnology company specializing in rare metabolic disease, where he led capital formation and allocation, investor relations, and corporate development since September 2015, after joining Aeglea as Vice President, Finance, in July 2014.

Before Aeglea, Mr. York held financial management roles in the life science, pharmaceutical and technology industries and began his career at PricewaterhouseCoopers LLP.

Charles is a CPA in the state of Arizona and received a B.S. in Accounting from the University of Connecticut and an MBA from the McCombs School of Business at the University of Texas at Austin.